Disclaimer

This presentation contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.
Agenda

Overview | Strategy

Mid-term Growth Prospects

Q1 2022 Results | FY 2022 Guidance

Appendix
A leading partner of the biopharma industry

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

The United Nations’ sustainability goal ‘Good Health and Well-Being’ is thus an integral part of our core business.
Sartorius Stedim Biotech at a glance

- **€2.89bn**
  - Sales revenue 2021

- **~23%**
  - Sales CAGR¹ 2016-2021

- **~35.8%**
  - EBITDA margin² 2021

- >25
  - countries, headquartered in Aubagne, France

- >10,400
  - Employees

Four strong pillars drive above-average growth

- **Pharma market** → CAGR 4-7%
- **Biopharma market** → CAGR ~10%
- **Single-use penetration** → Double-digit growth
- **Market share gains** → Esp. in North America

---

¹ In constant currencies  
² Excluding extraordinary items
Covering most steps of the biopharmaceutical manufacturing process

- Differentiated by the range and completeness of the portfolio
- Excellent positioning in key single-use technologies
- Internationally recognized supplier enabling innovation in bioprocessing through own R&D and partnerships

Overview | Strategy
Generating revenue throughout the lifecycle of a biopharma drug

<table>
<thead>
<tr>
<th>Stage</th>
<th>Preclinical (1 year)</th>
<th>Clinical (4-7 years)</th>
<th>Commercial (15+ years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scale</td>
<td>Process development</td>
<td>Proof of concept - pilot</td>
<td>Large</td>
</tr>
</tbody>
</table>

- Wide product range of equipment and consumables for all stages (from pre-commercial to large-scale manufacturing); optimal scalability
- Engineering support with excellent application knowhow and understanding of the entire bio-production process
- Production process of each individual drug is subject to validation by health authorities (e.g. FDA, EMA) and part of the drug approval
Integrated services and technologies for all types of biopharmaceuticals

- ~95% of revenue generated with bio/pharma customers
- Antibodies are most relevant; strong position in vaccines as well
- SSB provides solutions for the development and production of all biotechnologically derived drugs and cell derivatives
- These also include new modalities such as cell and gene therapies and viral vectors
The market landscape is dynamic across therapy modalities

**Protein-based therapies**
- mAbs
- Bi-/Multi-specifics
- Bioconjugates | ADCs
- Recombinant proteins and peptides
- Protein-based vaccines

**Viral-based therapies**
- Viral vectors for gene therapy
- Virus and viral vector vaccines
- Oncolytic viruses
- Novel modalities (e.g., mRNA, DNA, Exosomes)

**Advanced therapies**
- Cell therapy (e.g., iPSC, MSC)
- Gene-modified cell therapy (CAR-T)

**Unmet needs**
- Efficiency
- Yields
- Robust manufacturing

Share of molecules in R&D pipeline; source: Global Data, March 2021
Attractive market environment offers strong growth opportunities

**Growing and aging population**
- 9 billion people by 2050
- World population over age 60 in 2050: >2bn
- World population over 60 in 2021: ~1bn

**Biologics are gaining importance**
- Share of biologics in pharma end market
- Sales share of biologics in 2021: ~34%
- Sales share of biologics in 2026: ~37%
- CAGR for the biopharma market in 2021 – 2026: ~10%

---

Sales revenue more than doubled over the last 5 years

Sales CAGR  ~+19%
EBITDA\(^1\) margin  +14.9pp

~€477m


Sales revenue  EBITDA\(^1\) margin in %

~€1.05m

~€2.89bn

~+52.6%

+34.6%

+18.8%

+13.7%

+4.1%

+20.4%

+19.4%

+15.9%

+10.8%

+10.3%

Sales growth and CAGR in constant currencies 1 Excluding extraordinary items

Overview | Strategy
Regionalizing our supply chain and manufacturing; increasing our global capacity

**Germany | Göttingen, Guxhagen**
Production capacities increasing

**China and South Korea**
Capacities will be created in selected areas

**Puerto Rico and USA**
Capacities will be ramped up for selected areas

**Separation Instruments and systems**

**Separation Fluid management Cell culture media**

**Cell culture media Fluid management Customer interaction**
M&A strategy – adding innovation, enhancing focus

**Acquisition criteria**
- Portfolio: Complementary products or technologies
- Market position: Either among the Top 3 or unique selling point
- Integration: Management capacity; cultural fit
- Price: Fair valuation; reach Sartorius’ profitability level in 2-3 years

1. Acquired from Danaher

---

**Overview | Strategy**

M&A strategy – adding innovation, enhancing focus

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio Outsource</td>
<td>Cellca</td>
<td>kSep</td>
<td>Umetrics</td>
<td>Biological Industries</td>
<td>Life Science assets¹</td>
<td>BIA Separations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sartorius Stedim Biotech Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Recent acquisitions strengthen portfolio...

<table>
<thead>
<tr>
<th>Acquisition of selected life science assets from Danaher</th>
<th>Acquisition of BIA Separations</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$275m Purchase price</td>
<td>€360mn Purchase price</td>
</tr>
<tr>
<td>~$100m Sales revenue in 2019</td>
<td>~€25m Sales revenue in 2020e</td>
</tr>
<tr>
<td>+100 Employees</td>
<td>+120 Employees</td>
</tr>
<tr>
<td>May 2020 Date of consolidation</td>
<td>Nov. 2020 Date of consolidation</td>
</tr>
</tbody>
</table>

- Portfolio of upstream and downstream technologies
- Technology for purification in advanced therapy processes
...especially in downstream...

**Acquisition of WaterSep BioSeparations**

- **~$2.5m**
  - Sales revenue in 2020e

- **+15**
  - Employees

- **Dec. 2020**
  - Date of consolidation

- Innovative hollow fiber crossflow filtration units
- Purchase price $27mn plus earn-out

**Agreement to acquire chromatography process equipment division from Novasep**

- **~€37m**
  - Sales revenue in 2020e

- **+100**
  - Employees

- Resin-based batch and intensified chromatography systems
- Purchase price not disclosed; regulatory approvals pending
...and cell culture media...

**Acquisition of CellGenix**

- Sales revenue in 2020: ~€20m
- Employees: +70
- Date of consolidation: Jul. 2021

- Cell culture components for advanced therapies
- Transaction volume of €100m in cash for 51% stake

**Acquisition of Xell**

- Sales revenue in 2021e: ~€5m
- Employees: +35
- Date of consolidation: Aug. 2021

- Media and feed supplements for cell cultures
- Purchase price of around €50m + earn-out components

---

1 Remaining assets to be acquired at the beginning of 2023 and 2026
BIA Separations - Bioprocessing innovator, addressing bottlenecks in advanced therapies

- Ajdovščina, Slovenia
- ~120 employees
- Quadrupling production capacity till end 2021
- Acquired November 2020

Portfolio
- Pre-packed monolithic columns optimized for purification in advanced therapy processes (e.g. viruses, plasmids, exosomes)
- Provides significantly higher yield by avoiding shearing effects which occur in traditional purification processes, e.g. in chromatography

Positioning
- Monoliths already used in production of first commercialized advanced therapeutics
- Strong presence in (pre-) clinical projects
WaterSep BioSeparations – Further broadening our filtration portfolio

Marlborough, USA
~15 employees
R&D and production of membranes and cartridges
Acquired December 2020

Portfolio
- Hollow-fiber membrane devices and pre-sterilized assemblies for crossflow filtration applications in upstream and downstream
- Addresses customer needs for cost- and time-saving solutions

Strategic fit
- Complements offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing

Hollow fiber cartridges
CellGenix – Extending our cell culture media offering

**Freiburg, Germany**

~70 employees

GMP manufacturing and R&D laboratories

Acquired July 2021

**Portfolio**

- Critical cell culture components for advanced therapies
- Portfolio includes cytokines and growth factors, cell culture media, supplements and cells

**Strategic fit**

- Perfect fit with our existing media offering; combined portfolio makes us even more relevant for customers in this fast-growing segment of the biopharma market
- Freiburg to be established as a Group-wide competence center for the development and production of cell culture components
Xell – Another building block to establish a strong media business

- Bielefeld, Germany
- ~35 employees
- Major state-of-the-art capacity expansion recently completed
- Acquired July 2021

**Portfolio**
- Media and feed supplements for cell cultures; focus on viral vectors that are used in gene therapeutics and vaccines
- Analytical services for characterizing, screening, and quantifying media components, as well as for optimizing media composition

**Strategic fit**
- Expanding our current media offering by specialized media and strengthen media analytics capabilities
- Accelerating the expansion of our production network in this fast-growing area

Cell culture media and feed supplements
## Competitive portfolio across our relevant end-markets

<table>
<thead>
<tr>
<th>Category</th>
<th>SSB</th>
<th>Merck</th>
<th>Millipore</th>
<th>Pall</th>
<th>Danaher</th>
<th>Cytiva</th>
<th>Thermo Fisher</th>
<th>Top 3 Players</th>
</tr>
</thead>
</table>
| Filtration        |     |       |           |      |         |        |               | 1. Merck | Millipore  
2. Danaher | Pall  
3. Sartorius Stedim Biotech |
| Fluid Management  |     |       |           |      |         |        |               | 1. Sartorius Stedim Biotech  
2. Thermo Fisher  
3. Merck | Millipore |
| Fermentation      |     |       |           |      |         |        |               | 1. Sartorius Stedim Biotech  
2. Thermo Fisher  
3. Danaher | Cytiva |
| Purification      |     |       |           |      |         |        |               | 1. Danaher | Cytiva  
2. Merck | Millipore  
3. Sartorius Stedim Biotech |
| Cell Culture Media|     |       |           |      |         |        |               | 1. Thermo Fisher  
2. Merck | Millipore  
3. Danaher | Cytiva |

Pie charts indicate completeness of product offering

1 Formerly GE Biopharma
Pioneer and leader in the growing single-use technology market

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

- Capex|Opex reduction over entire lifecycle
- Reduced risk of cross-contamination
- Higher flexibility; advantageous for biosimilars

<table>
<thead>
<tr>
<th></th>
<th>Construction cost</th>
<th>Time-to-market</th>
<th>Energy cost</th>
<th>Water cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>-25-35%</td>
<td>-30-50%</td>
<td>-55-65%</td>
<td>-65-75%</td>
</tr>
<tr>
<td>Single-use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sartorius Stedim Biotech Group
Single-use allows manufacturers to mitigate investment risks

- Construction of stainless-steel based facilities takes longer and is more complex compared to single-use.
- Therefore, investment in stainless-steel facilities has to start in early clinical phase II.
- The construction of single-use facilities may start in clinical phase III, reducing investment risks of our clients.

<table>
<thead>
<tr>
<th>Clinical Phase I</th>
<th>Clinical Phase II</th>
<th>Clinical Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability that candidate advances to next stage</td>
<td>~ 60%</td>
<td>~ 30%</td>
</tr>
<tr>
<td>Probability of approval</td>
<td>~ 10%</td>
<td>~ 15%</td>
</tr>
</tbody>
</table>

Limited dependence on individual accounts

Long-term business relationships with leading global (bio-) pharma companies

- More than half of 2021 SSB sales were generated with the Top 50 customers
- Largest customer accounts for approx. 5% of SSB sales revenue
Our products are widely used in the development and production of biologics against COVID-19

We helped our customers to manage extremely challenging development timelines and to ease scaling of vaccine processes all the way to commercialization

- Education on SUT processes
- Delivery of key products across vaccine modalities (viral vectors, mRNA, proteins) and Covid-19 therapeutics
- Joint development of solutions with our application expertise

Vaccine development acceleration here to stay

- mRNA validated
- New technologies in manufacturing; capacity and technology decisions established
- Pace of development

Pandemic effects in 2021

- Pandemic-related net effect of around −18pp on sales revenue and around −13pp on order intake growth; consisting of investments in vaccine and therapeutic research and manufacturing, also inventory build-up
Agenda

Overview | Strategy

Mid-term Growth Prospects

Q1 2022 Results | FY 2022 Guidance

Appendix
2025 ambition – Updated profitability targets

- 2025 revenue target is based on the assumption of no pandemic-related sales (vs. €500m in FY21 and FY22)
- The margin target includes expenses for reduction of the company’s CO₂ emission intensity of around 1% of sales

Sartorius Stedim Biotech Group

<table>
<thead>
<tr>
<th>Sales revenue</th>
<th>€4bn unchanged</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA margin</td>
<td>&gt;35% previously ~33%</td>
</tr>
</tbody>
</table>

2025 targets are based on 2020 currency exchange rates; EBITDA excluding extraordinary items
U.S. remains most important market; China with highest growth rates

Biologics market growth forecast

<table>
<thead>
<tr>
<th>Region</th>
<th>2020</th>
<th>2024</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>119bn</td>
<td>167bn</td>
<td>+9% U.S.</td>
</tr>
<tr>
<td>Europe</td>
<td>46bn</td>
<td>58bn</td>
<td>+6% Europe</td>
</tr>
<tr>
<td>China</td>
<td>38bn</td>
<td>67bn</td>
<td>+15% China</td>
</tr>
<tr>
<td>ROW</td>
<td>47bn</td>
<td>72bn</td>
<td>+15% China</td>
</tr>
</tbody>
</table>

Sartorius Stedim Biotech Group
The Chinese market is in the next development phase

Dynamic increase in new biopharma companies

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>50</td>
<td>79</td>
<td>141</td>
</tr>
</tbody>
</table>

Increasingly focusing on innovative medicines

**Generics**

- Innovation 1.0
  - "fast follow" on validated or clinical targets

**Now**

- Innovation 2.0
  - Biologics innovators, indication expansion, technology modification

- Innovation 3.0
  - New modalities/New MOAs

Source: BCG, Sartorius

---

Mid-term Growth Prospects
Regional balance better reflecting end-markets

CAGR for continued operations, in constant currencies

<table>
<thead>
<tr>
<th>Region</th>
<th>2011</th>
<th>2021</th>
<th>2019</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asia</td>
<td>Pacific</td>
<td>20%</td>
<td>26%</td>
<td>28%</td>
</tr>
<tr>
<td>Americas</td>
<td>27%</td>
<td>33%</td>
<td>50%</td>
<td>~+20%</td>
</tr>
<tr>
<td>EMEA</td>
<td>53%</td>
<td>41%</td>
<td>22%</td>
<td>~+18%</td>
</tr>
</tbody>
</table>
Biosimilars: Strong growth, big opportunities

- Major blockbuster biologics are going off-patent
- Time-to-market is key as only the first providers are most likely profitable
- Several approvals in Asia and Europe; U.S. at the beginning
- For now, relatively small market but with strong growth
- Single-use is the preferred platform for biosimilars

Biosimilars will outperform the biologics market

€ in billions

<table>
<thead>
<tr>
<th>Year</th>
<th>Biosimilars</th>
<th>Other Biologics</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>~14.5</td>
<td>~235.5</td>
</tr>
<tr>
<td>2024</td>
<td>~41.5</td>
<td>~323.5</td>
</tr>
</tbody>
</table>

~+30% CAGR

Growing number of biosimilar approvals

E.U. and U.S.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>7</td>
<td>22</td>
<td>20</td>
<td>15</td>
<td>16</td>
</tr>
</tbody>
</table>
High innovation dynamics in Biopharma

Development of new drugs and vaccines must be accelerated, e.g. through more automation.

Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars.

New tools and methods required e.g. for novel cell and gene therapies.

Future drug manufacturing is more automated, intensified and scalable.
Analytical technologies to improve process economics and safety

- Bioprocess sensors, analyzers and software
- Collect, monitor and control quality-critical parameters
- Analyze data to obtain a better process understanding
- Use knowledge for process development, optimization and automation
- Allows customers to increase time-to-market, to reduce COGS, to improve process robustness and product quality
- Intention to upgrade Umetrics software suite with advanced analytics technologies such as AI and machine learning
- Data analytics just at the beginning in biomanufacturing with high potential
Agenda

Overview | Strategy

Mid-term Growth Prospects

Q1 2022 Results | FY 2022 Guidance

Appendix
### Strong organic growth; further margin increase

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>Q1 2021</th>
<th>Q1 2022</th>
<th>▲ in %</th>
<th>▲ in % cc(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue</td>
<td>655.2</td>
<td>862.5</td>
<td>+31.6</td>
<td>+27.6</td>
</tr>
<tr>
<td>Order intake</td>
<td>1,004.4</td>
<td>949.7</td>
<td>-5.5</td>
<td>-8.6</td>
</tr>
<tr>
<td>Underlying EBITDA(^2)</td>
<td>231.6</td>
<td>303.7</td>
<td>31.1</td>
<td></td>
</tr>
<tr>
<td>Underlying EBITDA(^2) margin in %</td>
<td>35.4</td>
<td>35.2</td>
<td>-0.2pp</td>
<td></td>
</tr>
<tr>
<td>Underlying EPS(^3) in €</td>
<td>1.64</td>
<td>2.21</td>
<td>+34.5</td>
<td></td>
</tr>
</tbody>
</table>

- High demand across the portfolio; acquisitions contribute around 2pp to sales growth
- OI is normalizing as expected; prior-year figure impacted by pandemic and changed ordering patterns by some customers
- Underlying EBITDA margin influenced by FX headwinds and higher costs for logistics and materials

---

1 Constant currencies  
2 Underlying = excluding extraordinary items  
3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
High double-digit sales growth in all regions led by the Americas

- Dynamic increase in the Americas
- EMEA with substantial growth against high comparables
- Strong growth in Asia|Pacific

**Sales by Region**

**Americas**
- Q1 2021: €204.0m
- Q1 2022: €293.7m
- Growth: +34.7%

**EMEA**
- Q1 2021: €284.1m
- Q1 2022: €348.6m
- Growth: +22.9%

**Asia|Pacific**
- Q1 2021: €167.1m
- Q1 2022: €220.2m
- Growth: +26.9%

**Acc. to customers' location; growth in constant currencies**
### Sartorius Stedim Biotech Group

<table>
<thead>
<tr>
<th></th>
<th>Q1 2021</th>
<th>Q1 2022</th>
<th>▲ in %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underlying EBITDA</td>
<td>231.6</td>
<td>303.7</td>
<td>+31.1</td>
</tr>
<tr>
<td>Extraordinary items</td>
<td>-1.7</td>
<td>-1.8</td>
<td>-3.1</td>
</tr>
<tr>
<td>Financial result</td>
<td>-15.9</td>
<td>76.5</td>
<td>n.m.</td>
</tr>
<tr>
<td>Underlying net profit&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>151.3</td>
<td>203.4</td>
<td>+34.4</td>
</tr>
<tr>
<td>Reported net profit&lt;sup&gt;2&lt;/sup&gt;</td>
<td>125.8</td>
<td>270.1</td>
<td>114.7</td>
</tr>
<tr>
<td>Operating cash flow</td>
<td>204.0</td>
<td>169.2</td>
<td>-17.1</td>
</tr>
<tr>
<td>Investing cash flow&lt;sup&gt;3&lt;/sup&gt;</td>
<td>-62.3</td>
<td>-121.0</td>
<td>-94.2</td>
</tr>
<tr>
<td>CAPEX ratio (in %)</td>
<td>9.5</td>
<td>8.9</td>
<td>-0.5pp</td>
</tr>
</tbody>
</table>

- Cash flow influenced by higher inventories to support supply security
- Financial result mainly driven by valuation effect of earn-out liability regarding BIA Separations
- Investing cash flow reflects substantial CAPEX program and M&A

---

Q1 2021 figures restated due to final PPA for the acquisitions of BIA Separations and WaterSep BioSeparations 1

Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and a normalized tax rate 2

After non-controlling interest 3

Net cash flow from investing activities and acquisitions
Robust financial indicators; low dynamic debt ratio

Key Financial Indicators

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>Dec. 31, 2021</th>
<th>Mar. 31, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity ratio in %</td>
<td>43.9</td>
<td>48.1</td>
</tr>
<tr>
<td>Net debt in millions of €</td>
<td>401.9</td>
<td>465.7</td>
</tr>
<tr>
<td>Net debt</td>
<td>underlying EBITDA¹</td>
<td>0.4</td>
</tr>
</tbody>
</table>

¹ Includes underlying pro forma EBITDA of acquisitions completed in 2021 and 2022

Net Debt and Net Debt to Underlying EBITDA

Graph showing net debt in millions of € (lhs) and net debt to underlying EBITDA (rhs) from Q1-Q4 2014 to Q1-Q4 2022.
Guidance 2022 confirmed: Double-digit sales growth, sustained high profitability; uncertainties yet on a further elevated level

<table>
<thead>
<tr>
<th>Guidance 2022</th>
<th>Sales revenue growth</th>
<th>Underlying EBITDA margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius Stedim Biotech Group</td>
<td>~15% - 19%</td>
<td>&gt;35%</td>
</tr>
<tr>
<td>thereof from acquisitions</td>
<td>~2pp</td>
<td></td>
</tr>
</tbody>
</table>

- Margin target includes expenses for reduction of CO₂ emission intensity of approx. 0.5% of sales
- CAPEX ratio expected at around 14.5%
- Net debt to underlying EBITDA anticipated at around 0.2

1 In constant currencies
Agenda

Overview | Strategy
Mid-term Growth Prospects
Q1 2022 Results | FY 2022 Guidance

Appendix
To Sartorius Stedim Biotech, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

Please click below for further financial information:

- Earnings Release Q1 2022
- Annual Report 2021
- Earnings Release 9M 2021
- Half-Year Report H1 2021
Sartorius Stedim Biotech shares – an attractive investment

<table>
<thead>
<tr>
<th>Biopharma market fueled by long-term growth drivers</th>
<th>Leading market positions in key technologies and high brand awareness</th>
<th>Global presence with strong base in growth regions</th>
</tr>
</thead>
<tbody>
<tr>
<td>High entry barriers, low price-sensitivity and consolidated competitive landscape</td>
<td>Diversified revenue base and high share of recurring revenues provide low volatility</td>
<td>Proven growth track record: Sales CAGR(^1) of (\sim 16.5%) over the last five years</td>
</tr>
</tbody>
</table>

\(^1\) In constant currencies
**Sartorius Stedim Biotech Group**

**Share price performance**

<table>
<thead>
<tr>
<th>ISIN</th>
<th>Number of shares</th>
<th>Indices</th>
</tr>
</thead>
<tbody>
<tr>
<td>FR0013154002</td>
<td>92,180,190</td>
<td>SBF 120</td>
</tr>
</tbody>
</table>

**Market cap.**

€31.5bn (as of April 20, 2022)
A sampling of the product portfolio

Filtration

Purification

Fermentation

Fluid management
Contacts and Financial calendar

- **July 21, 2022**
  Publication first-half 2022 Results

- **October 19, 2022**
  Publication nine-months 2022 Results

---

**Petra Kirchhoff**
Head of Corporate Communications & IR
+49.551.308.1686
petra.kirchhoff@sartorius.com

**Petra Müller**
Head of Investor Relations
+49.551.308.6035
petra.mueller2@sartorius.com

**Mirko Koch**
Manager Investor Relations
+49.551.308.2402
mirko.koch@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany